O'Donovan D, Horowitz M, Russo A, Feinle-Bisset C, Murolo N, Gentilcore D, Wishart J M, Morris H A, Jones K L
Department of Medicine, University of Adelaide, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia.
Diabetologia. 2004 Dec;47(12):2208-14. doi: 10.1007/s00125-004-1591-4. Epub 2004 Dec 15.
AIMS/HYPOTHESES: We examined the effects of lipase inhibition with orlistat on (i) gastric emptying of, and (ii) the glycaemic, glucagon-like peptide-1 (GLP-1) and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetic patients.
Eight type 2 diabetic patients, who were aged 62 years (median range: 49-68 years) and managed by diet alone, consumed a meal containing 65 g powdered potato, 20 g glucose reconstituted with 200 ml water (labelled with 20 MBq (99m)Tc-sulphur-colloid) and 45 g margarine. They did this on two separate occasions, with and without 120 mg orlistat, and while in the seated position with their back against a gamma camera. Venous blood samples for measurement of blood glucose, plasma insulin and GLP-1 were obtained immediately before the meal and at regular intervals afterwards. Blood pressure (systolic and diastolic) and heart rate were measured using an automated device.
Gastric emptying of the meal was faster after orlistat than without orlistat (50% emptying time [mean +/- SEM], 61+/-8 min vs 98+/-5 min; p=0.0001). In the first 60 min after the meal blood glucose (p=0.001) and plasma insulin (p=0.01) concentrations were higher in patients who had taken orlistat; between 60 and 180 min plasma GLP-1 (p=0.02) concentrations were lower after orlistat than without orlistat. Between 0 and 30 min systolic blood pressure (p=0.003) was lower, and heart rate (p=0.03) greater in subjects who had taken orlistat than in those who had not.
CONCLUSIONS/INTERPRETATION: Inhibition of fat digestion by orlistat may-as a result of more rapid gastric emptying-exacerbate postprandial glycaemia and the postprandial fall in blood pressure in patients with type 2 diabetes after ingestion of meals containing fat and carbohydrate.
目的/假设:我们研究了使用奥利司他抑制脂肪酶对2型糖尿病患者的以下影响:(i)高脂/高碳水化合物餐后胃排空情况,以及(ii)血糖、胰高血糖素样肽-1(GLP-1)水平和心血管反应。
8名2型糖尿病患者,年龄62岁(中位数范围:49 - 68岁),仅通过饮食控制,食用了一顿包含65克土豆粉、20克用200毫升水复溶的葡萄糖(标记有20兆贝可(99m)锝-硫胶体)和45克人造黄油的餐食。他们在两个不同场合分别进行,一次服用120毫克奥利司他,另一次不服用,且坐在背靠γ相机的位置。在进餐前及进餐之后定期采集静脉血样,用于测量血糖、血浆胰岛素和GLP-1。使用自动设备测量血压(收缩压和舒张压)和心率。
服用奥利司他后餐食的胃排空比未服用时更快(50%排空时间[平均值±标准误],61±8分钟对98±5分钟;p = 0.0001)。进餐后头60分钟内,服用奥利司他的患者血糖(p = 0.001)和血浆胰岛素(p = 0.01)浓度更高;在60至180分钟之间,服用奥利司他后的血浆GLP-1浓度(p = 0.02)低于未服用时。在0至30分钟之间,服用奥利司他的受试者收缩压(p = 0.00)更低,心率(p = 0.03)更高。
结论/解读:奥利司他抑制脂肪消化可能由于胃排空更快,从而加剧2型糖尿病患者在摄入含脂肪和碳水化合物的餐后的餐后血糖升高以及餐后血压下降。